skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 52,490  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
The Tumor Microenvironment of High Grade Serous Ovarian Cancer
The Tumor Microenvironment of High Grade Serous Ovarian Cancer
Material Type:
Book 		Add to My Research

The Tumor Microenvironment of High Grade Serous Ovarian Cancer

https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode ;ISBN: 9783038975557 ;ISBN: 3038975559 ;ISBN: 9783038975540 ;ISBN: 3038975540 ;DOI: 10.3390/books978-3-03897-555-7

Full text available

Citations Cited by
2
Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis
Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis
Material Type:
Article 		Add to My Research

Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis

Breast cancer (Tokyo, Japan), 2021-11, Vol.28 (6), p.1167-1180 [Peer Reviewed Journal]

The Author(s) 2020 ;ISSN: 1340-6868 ;EISSN: 1880-4233 ;DOI: 10.1007/s12282-020-01148-2

Digital Resources/Online E-Resources

Citations Cited by
3
71 Integrated multi-omic and clinicopathological analysis of high-grade serous ovarian cancer in BRCA1/2 mutated patients with poor survival: identification of predictive biomarkers for personalized treatment
71 Integrated multi-omic and clinicopathological analysis of high-grade serous ovarian cancer in BRCA1/2 mutated patients with poor survival: identification of predictive biomarkers for personalized treatment
Material Type:
Conference Proceeding 		Add to My Research

71 Integrated multi-omic and clinicopathological analysis of high-grade serous ovarian cancer in BRCA1/2 mutated patients with poor survival: identification of predictive biomarkers for personalized treatment

International journal of gynecological cancer, 2023, Vol.33 (Suppl 3), p.A32-A33 [Peer Reviewed Journal]

2023 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2023-ESGO.49

Full text available

Citations Cited by
4
72 Ovarian cancer audit of a UK tertiary centre over the past 3 years
72 Ovarian cancer audit of a UK tertiary centre over the past 3 years
Material Type:
Conference Proceeding 		Add to My Research

72 Ovarian cancer audit of a UK tertiary centre over the past 3 years

International journal of gynecological cancer, 2023, Vol.33 (Suppl 3), p.A244-A244 [Peer Reviewed Journal]

2023 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2023-ESGO.508

Full text available

Citations Cited by
5
471 PARP-inhibitors can be applied together with tumor treating fields (TTFields) to prolong survival in an ovarian cancer mouse model
471 PARP-inhibitors can be applied together with tumor treating fields (TTFields) to prolong survival in an ovarian cancer mouse model
Material Type:
Conference Proceeding 		Add to My Research

471 PARP-inhibitors can be applied together with tumor treating fields (TTFields) to prolong survival in an ovarian cancer mouse model

International journal of gynecological cancer, 2023, Vol.33 (Suppl 3), p.A282-A282 [Peer Reviewed Journal]

2023 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2023-ESGO.585

Full text available

Citations Cited by
6
811 Ovarian tumor organotypic slices cultures for functional drug screening (TOSCA)
811 Ovarian tumor organotypic slices cultures for functional drug screening (TOSCA)
Material Type:
Conference Proceeding 		Add to My Research

811 Ovarian tumor organotypic slices cultures for functional drug screening (TOSCA)

International journal of gynecological cancer, 2023, Vol.33 (Suppl 3), p.A417-A417 [Peer Reviewed Journal]

2023 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2023-ESGO.881

Full text available

Citations Cited by
7
863 The role of pegylated liposomal doxorubicin and weekly paclitaxel with or without bevacizumab in prolonging the platinum-free interval in epithelial ovarian cancer
863 The role of pegylated liposomal doxorubicin and weekly paclitaxel with or without bevacizumab in prolonging the platinum-free interval in epithelial ovarian cancer
Material Type:
Conference Proceeding 		Add to My Research

863 The role of pegylated liposomal doxorubicin and weekly paclitaxel with or without bevacizumab in prolonging the platinum-free interval in epithelial ovarian cancer

International journal of gynecological cancer, 2023, Vol.33 (Suppl 3), p.A317-A317 [Peer Reviewed Journal]

2023 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2023-ESGO.663

Full text available

Citations Cited by
8
514 Potential targeted therapies for ovarian cancer beyond PARP inhibitors (review)
514 Potential targeted therapies for ovarian cancer beyond PARP inhibitors (review)
Material Type:
Conference Proceeding 		Add to My Research

514 Potential targeted therapies for ovarian cancer beyond PARP inhibitors (review)

International journal of gynecological cancer, 2023, Vol.33 (Suppl 3), p.A286-A287 [Peer Reviewed Journal]

2023 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2023-ESGO.595

Full text available

Citations Cited by
9
Cell Origins of High-Grade Serous Ovarian Cancer
Cell Origins of High-Grade Serous Ovarian Cancer
Material Type:
Article 		Add to My Research

Cell Origins of High-Grade Serous Ovarian Cancer

Cancers, 2018-11, Vol.10 (11), p.433 [Peer Reviewed Journal]

2018 by the authors. 2018 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers10110433 ;PMID: 30424539

Full text available

Citations Cited by
10
2022-RA-785-ESGO Radical surgical procedures in advanced ovarian cancer and differences between primary and interval debulking surgery
2022-RA-785-ESGO Radical surgical procedures in advanced ovarian cancer and differences between primary and interval debulking surgery
Material Type:
Article 		Add to My Research

2022-RA-785-ESGO Radical surgical procedures in advanced ovarian cancer and differences between primary and interval debulking surgery

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A262-A262 [Peer Reviewed Journal]

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.558

Full text available

Citations Cited by
11
2022-RA-1237-ESGO Predictors of PARP inhibitors toxicities and the toxicity impact on overall survival in advanced ovarian cancer
2022-RA-1237-ESGO Predictors of PARP inhibitors toxicities and the toxicity impact on overall survival in advanced ovarian cancer
Material Type:
Article 		Add to My Research

2022-RA-1237-ESGO Predictors of PARP inhibitors toxicities and the toxicity impact on overall survival in advanced ovarian cancer

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A312-A312 [Peer Reviewed Journal]

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.666

Full text available

Citations Cited by
12
2022-RA-1551-ESGO Impact of age on first line treatments of ovarian cancer and their outcomes: results from the Unicancer ESME OVR real-world database
2022-RA-1551-ESGO Impact of age on first line treatments of ovarian cancer and their outcomes: results from the Unicancer ESME OVR real-world database
Material Type:
Article 		Add to My Research

2022-RA-1551-ESGO Impact of age on first line treatments of ovarian cancer and their outcomes: results from the Unicancer ESME OVR real-world database

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A348-A349 [Peer Reviewed Journal]

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.741

Full text available

Citations Cited by
13
2022-RA-884-ESGO Whole-body diffusion-weighted MRI (WB-DWI/MRI) for the prediction of resectable disease at the time of secondary cytoreductive surgery for relapsed epithelial ovarian cancer
2022-RA-884-ESGO Whole-body diffusion-weighted MRI (WB-DWI/MRI) for the prediction of resectable disease at the time of secondary cytoreductive surgery for relapsed epithelial ovarian cancer
Material Type:
Article 		Add to My Research

2022-RA-884-ESGO Whole-body diffusion-weighted MRI (WB-DWI/MRI) for the prediction of resectable disease at the time of secondary cytoreductive surgery for relapsed epithelial ovarian cancer

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A273-A274 [Peer Reviewed Journal]

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.583

Full text available

Citations Cited by
14
2022-RA-1557-ESGO Mesenteric lymph node involvement in patients undergoing a bowel resection during debulking surgery in advanced ovarian cancer
2022-RA-1557-ESGO Mesenteric lymph node involvement in patients undergoing a bowel resection during debulking surgery in advanced ovarian cancer
Material Type:
Article 		Add to My Research

2022-RA-1557-ESGO Mesenteric lymph node involvement in patients undergoing a bowel resection during debulking surgery in advanced ovarian cancer

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A349-A349 [Peer Reviewed Journal]

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.744

Full text available

Citations Cited by
15
2022-VA-1146-ESGO Conservative endoscopic management of a colorectal leakage in advanced ovarian cancer
2022-VA-1146-ESGO Conservative endoscopic management of a colorectal leakage in advanced ovarian cancer
Material Type:
Article 		Add to My Research

2022-VA-1146-ESGO Conservative endoscopic management of a colorectal leakage in advanced ovarian cancer

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A305-A305 [Peer Reviewed Journal]

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.650

Full text available

Citations Cited by
16
2022-RA-1215-ESGO The prognostic impact of Preoperative LMRof the body fluid in patients with epithelial ovarian cancer
2022-RA-1215-ESGO The prognostic impact of Preoperative LMRof the body fluid in patients with epithelial ovarian cancer
Material Type:
Article 		Add to My Research

2022-RA-1215-ESGO The prognostic impact of Preoperative LMRof the body fluid in patients with epithelial ovarian cancer

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A311-A311 [Peer Reviewed Journal]

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.662

Full text available

Citations Cited by
17
2022-RA-1694-ESGO A dynamic, risk-based determination of follow-upintervalsfor advanced epithelial ovarian cancer based on serum ca125 tests
2022-RA-1694-ESGO A dynamic, risk-based determination of follow-upintervalsfor advanced epithelial ovarian cancer based on serum ca125 tests
Material Type:
Article 		Add to My Research

2022-RA-1694-ESGO A dynamic, risk-based determination of follow-upintervalsfor advanced epithelial ovarian cancer based on serum ca125 tests

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A362-A363 [Peer Reviewed Journal]

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.776

Full text available

Citations Cited by
18
2022-RA-634-ESGO Trabectedin plus pegylated liposomaldoxorubicin in patients who experienced disease progression after PARPi maintenance: a real life case-control study
2022-RA-634-ESGO Trabectedin plus pegylated liposomaldoxorubicin in patients who experienced disease progression after PARPi maintenance: a real life case-control study
Material Type:
Article 		Add to My Research

2022-RA-634-ESGO Trabectedin plus pegylated liposomaldoxorubicin in patients who experienced disease progression after PARPi maintenance: a real life case-control study

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A247-A247 [Peer Reviewed Journal]

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.530

Full text available

Citations Cited by
19
2022-RA-1637-ESGO HIPEC as a safe and useful tool for the treatment of ovarian cancer
2022-RA-1637-ESGO HIPEC as a safe and useful tool for the treatment of ovarian cancer
Material Type:
Article 		Add to My Research

2022-RA-1637-ESGO HIPEC as a safe and useful tool for the treatment of ovarian cancer

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A356-A356 [Peer Reviewed Journal]

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.761

Full text available

Citations Cited by
20
2022-RA-830-ESGO Expression of COL5A2 in ovarian tumor microenvironment and its mechanism of promoting ovarian cancer
2022-RA-830-ESGO Expression of COL5A2 in ovarian tumor microenvironment and its mechanism of promoting ovarian cancer
Material Type:
Article 		Add to My Research

2022-RA-830-ESGO Expression of COL5A2 in ovarian tumor microenvironment and its mechanism of promoting ovarian cancer

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A267-A268 [Peer Reviewed Journal]

IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 1048-891X ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2022-ESGO.571

Full text available

Citations Cited by

Results 1 - 20 of 52,490  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (43,553)

Refine My Results

New Records 

  1. New From Last Week  (11)
  2. New From Last Month  (164)
  3. New From Last 3 Month  (714)
  4. More options open sub menu

Subject 

  1. Ovarian Cancer  (49,608)
  2. Science & Technology  (37,181)
  3. Life Sciences & Biomedicine  (33,687)
  4. Humans  (23,857)
  5. Female  (20,967)
  6. Oncology  (19,052)
  7. Tumors  (14,173)
  8. Cancer  (11,752)
  9. Chemotherapy  (10,809)
  10. Breast Cancer  (9,831)
  11. Cancer Therapies  (8,650)
  12. Middle Aged  (8,125)
  13. Ovarian Neoplasms - Pathology  (7,668)
  14. Proteins  (7,354)
  15. Metastasis  (7,069)
  16. Medical Prognosis  (6,891)
  17. Patients  (6,773)
  18. Adult  (6,534)
  19. Gene Expression  (6,463)
  20. Mutation  (6,185)
  21. More options open sub menu

Language 

  1. English  (51,625)
  2. Japanese  (5,260)
  3. German  (273)
  4. Korean  (206)
  5. Chinese  (177)
  6. French  (150)
  7. Polish  (145)
  8. Spanish  (118)
  9. Portuguese  (110)
  10. Russian  (104)
  11. Norwegian  (42)
  12. Turkish  (39)
  13. Persian  (28)
  14. Czech  (8)
  15. Catalan  (8)
  16. Italian  (5)
  17. Ukrainian  (5)
  18. Croatian  (4)
  19. Arabic  (2)
  20. Romanian  (2)
  21. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait